Incannex Healthcare (IXHL) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for December 11, 2024, in New York, with voting on key proposals including director election, auditor ratification, and significant stock issuances tied to financing agreements.

• Stockholders of record as of October 24, 2024, are eligible to vote, with multiple voting methods available including internet, phone, mail, and in-person.

• The proxy statement includes information on board structure, executive compensation, equity plans, audit matters, and related party transactions.

Voting matters and shareholder proposals

• Election of one director (Peter Widdows) for a three-year term expiring in 2027.

• Ratification of Grant Thornton Audit Pty Ltd as independent auditor for fiscal year ending June 30, 2025.

• Approval to issue 20% or more of outstanding common stock under an equity line of credit with Arena Global, including commitment fee shares and a warrant.

• Approval to issue 20% or more of outstanding common stock under a securities purchase agreement with purchasers, including debenture conversions and warrant exercises.

• Approval of any adjournment of the meeting to solicit additional proxies if needed.

Board of directors and corporate governance

• The board consists of five members divided into three classes, with staggered terms.

• Three directors are considered independent under Nasdaq rules; two are not.

• Audit and compensation committees are in place, with written charters and annual reviews.

• No separate nominating committee; independent directors oversee nominations and board diversity.

• Current board composition does not meet Nasdaq diversity requirements but is reviewed regularly.